Healthcare - Biotechnology - NASDAQ - US
$ 41.96
-8.67 %
$ 2.72 B
Market Cap
-19.61
P/E
CASH FLOW STATEMENT
-103 M
OPERATING CASH FLOW
140 M
INVESTING CASH FLOW
4.19 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Kymera Therapeutics, Inc.
| Net Income | -147 M |
| Depreciation & Amortization | 3.56 M |
| Capital Expenditures | -34.5 M |
| Stock-Based Compensation | 43.1 M |
| Change in Working Capital | 2.68 M |
| Others | -13 M |
| Free Cash Flow | -137 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (147.0) | (154.8) | (100.2) | (45.6) | (41.2) | (21.5) |
| Depreciation & Amortization | 3.6 | 3.0 | 2.4 | 1.8 | 0.8 | 0.2 |
| Deferred Income Tax | 0 | 0 | 0 | 1.6 | 0 | 0 |
| Stock Based Compensation | 43.1 | 35.5 | 25.0 | 5.2 | 1.2 | 0.6 |
| Other Operating Activities | (5.2) | 0.9 | 5.8 | 0.3 | 0.4 | 0.4 |
| Change in Working Capital | 2.7 | (37.6) | (61.9) | 124.9 | 56.7 | 2.3 |
| Cash From Operations | (102.8) | (153.1) | (128.9) | 88.1 | 17.9 | (17.9) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (34.5) | (2.8) | (1.6) | (9.1) | (0.5) | (1.4) |
| Other Items | 174.4 | 23.4 | (98.2) | (413.5) | (16.0) | 0 |
| Cash From Investing Activities | 139.9 | 20.5 | (99.8) | (422.6) | (16.5) | (1.4) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 76 K | (1.1) | (0.8) | (0.6) | (0.4) | (0.3) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.3 | 4.3 | 8.0 | 93.1 | 35.3 | 53.2 |
| Cash From Financing Activities | 4.2 | 153.0 | 250.3 | 289.3 | 34.9 | 52.9 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 41.3 | 20.4 | 21.5 | (45.2) | 36.3 | 33.7 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (137.3) | (155.9) | (130.5) | 79.0 | 17.4 | (19.2) |